Abstract
Regenerative injection therapy is an evolving interventional treatment that provides alternative solutions for different musculoskeletal conditions. Recent advances in research and scientific knowledge regarding regenerative therapies for neuromusculoskeletal conditions have evolved from a mere alternative therapy to a more specific treatment of musculoskeletal conditions. In fact, the surge in research on regenerative medicine have shown the varied interest of different specialties on the potential of this treatment. The gap between conservative and surgical options has been bridged with the advent of this technology, allowing physicians to postpone an operative procedure in favor of this intervention with some operative procedures incorporating the use of regenerative therapies either to shorten the time of recovery or return to play especially for some elite athletes. Although this treatment modality has been challenged by some physicians and accepted by others, the amount of progress in the development of new approaches in the preparation, isolation, administration of regenerative products, and the understanding of its biologic mechanisms and molecular components shift the momentum in favor of its use as a modern tool for treating different musculoskeletal injuries. The lack of long-term efficacy of existing therapies also contributes to why there is an increasing interest in its use. In addition, patients and healthcare providers alike raise a common concern about the safety of oral medications for prolonged use in the presence of comorbidities. Thus, regenerative therapies, being an autologous source have the potential of providing the needed answer to these concerns with an added advantage of minimal safety issues, ease of administration and less immune reactions. Additionally, the advent of musculoskeletal ultrasound complements the procedure by its portability and dynamic feature. A better view of the target site makes it a point of care modality assuring both patients and physicians that the intended injection site with the regenerative solutions are precisely delivered. it also ensures that no vital structures were affected during the injection procedure. While it is true that regenerative injection therapy is a modern intervention used in addressing musculoskeletal conditions, the use of ultrasound is a much needed tool to ensure that the solution is delivered appropriately.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Finnoff ND, Henning P, Hollman J, Smith J. Accuracy of ultrasound-guided versus unguided pes anserine bursa injections. PM & R. 2010;8:732–9.
Hashiuchi T, Sakurai G, Morimoto M, Komei T, Yoshinori T, Tanaka Y. Accuracy of the biceps tendon sheath injection: ultrasound-guided or unguided injection? A randomized controlled trial. J Shoulder Elb Surg. 2011;20(7):1069–73.
Peck E, Lai JK, Pawlina W, Smith J. Accuracy of ultrasound-guided versus palpation guided acromioclavicular joint injections: a cadaveric study. PM & R. 2010;2(9):817–21.
Daley E, Bajaj S, Bisson L, Cole B. Improving injection accuracy of the elbow, knee, and shoulder; does injection site and imaging make a difference? A systematic review. Am J Sports Med. 2011;39:656–62.
Furtado RN, Pereira DF, Rodriguez da Luz K, dos Santos MF, Konal MS, SDV M, Rosenfeld A, ARC F, Natour J. Effectiveness of imaging-guided intraarcticular injection: a comparison study between fluoroscopy and ultrasound. Rev Bras Reumatol. 2013;53(6):476–82.
Koski JM, Hammer HB. Ultrasound-guided procedures: techniques and usefulness in controlling inflammation and disease progression. Rheumatology. 2012;51:731–5.
Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85(6):638–46.
Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999;14(4):529–35.
Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med. 2006;34(11):1774–8.
Nguyen RT, Borg-stein J, McInnis K. Applications of platelet-rich plasma in musculoskeletal and sports medicine: an evidence-based approach. PM & R. 2011;3(3):226–50.
Mishra A, Harmon K, Woodall J, Vieira A. Sports medicine applications of platelet-rich plasma. Curr Pharma Biotechnol. 2012;13(7):1185–95.
Malanga GA, Goldin M. PRP: review of the current evidence for musculoskeletal conditions. Curr Phys Med Rehabil Rep. 2014;2:1–5.
Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001;10(4):225–8.
Cerciello S, Beitzel K, Howlett N, Russell RP, Apostolakos J, McCarthy MB, Cote MP, Mazzocca AD. The use of platelet-rich plasma preparations in the treatment of musculoskeletal injuries in orthopaedic sports medicine. Op Tech Orthop. 2013:23(2):69–74.
Oh JH, Kim W, Park KU, et al. Comparison of the cellular composition and cytokine-release kinetics of various platelet-rich plasma preparations. Am J Sports Med. 2015;43(12):3062–70.
Kevy S, Jacobson M, Mandle R. Defining the composition and healing effect of platelet-rich plasma. Presented at the Platelet-rich Plasma Symposium, New York, 5 Aug 2010.
Giusti RA, D’Ascenzo S, Millimaggi D, Pavan A, Dell’Orso L, Dolo V. Identification of an optimal concentration of platelet gel for promoting angiogenesis in human endothelial cells. Transfusion. 2009;49(4):771–8.
Foster TE, Puskas BL, Mendelbaum BR, et al. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009;37:2259–72.
Wasterlain AS, Braun HJ, Dragoo JL. Contents and formulations of platelet-rich plasma. Op Tech Orthop. 2012;22(1):33–42.
Anitua E, Sanchez M, Nurden AT, Zalduendo MM, de la Fuente M, Azofra J, Andia I. Platelet-released growth factors enhance the secretion of hyaluronic acid and induce hepatocyte growth factor production by synovial fibroblasts from arthritic patients. Rheumatology. 2007;46(12):1769–72.
Jo CH, Kim JE, Yoon KS, Shin S. Platelet-rich plasma stimulates cell proliferation and enhances matrix gene expression and synthesis in tenocytes from human rotator cuff tendons with degenerative tears. Am J Sports Med. 2012;40(5):1035–45.
Braun HJ, Kim HJ, Chu CR, Dragoo JL. The effect of platelet-rich plasma formulations and blood products on human synoviocytes implications for intra-articular injury and therapy. Am J Sports Med. 2014;42(5):1204–10.
Fitzpatrick J, Bulsara MK, O’Donnell J, Zheng MH. Leucocyte-rich platelet-rich plasma treatment of gluteus medius and minimus tendinopathy: a double-blind randomized controlled trial with 2-year follow-up. Am J Sports Med. 2019;47(5):1130–7.
Miroshnychenko O, Chang WT, Dragoo JL. The use of platelet-rich plasma and platelet-poor plasma to enhance differentiation of skeletal myoblasts: implications for the use of autologous blood products for muscle regeneration. Am J Sports Med. 2017;45(4):945–53.
Hooiveld M, Roosendaal G, Wenting MJG, van den Berg HM. Short-term exposure of cartilage to blood results in chondrocyte apoptosis. Am J Pathol. 2003;162(3):943–51.
Roosendaal G, Vianen ME, Marx JJ, et al. Blood-induced joint damage: a human in vitro study. Arthritis Rheuma. 1999;42(5):1025–32.
DeLong JM, Russell RP, Mazzocca AD. Platelet-rich plasma: the PAW classification system. Arthroscopy. 2012;28(7):998–1009.
Mautner K, Malanga GA, Smith J, Shiple B. A call for a standard classification system for future biologic research: the rationale for new PRP nomenclature. PM & R. 2015;7(4 Suppl):S53–9.
Lana JF, Purita J, Paulus C, Huber SC, Rodrigues B, Rodrigues AA, Santana MH, Madureira JL, Luzo ACM, Belangero WD, Annichino-Bizzacchi JM. Contributions for classification of platelet-rich plasma--proposal of a new classification: MARSPILL. Regen Med. 2017;12(5):565–74.
Dohan Ehrenfest DM, Rasmussen L, et al. Classification of platelet concentrates; from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27(3):158–67.
Schippinger G, Pruller F, Divjak M, et al. Autologous platelet-rich plasma preparation influence of nonsteroidal anti-inflammatory drugs on platelet function. Orthop J Sports Med. 2015;3:6.
Amaral R, Silva N, Haddad N, Lopes L, Ferreira F, Filho R, Cappelletti P, de Mello W, Cordeiro-Spinetti E, Balduino A. Platelet-rich plasma obtained with different anticoagulants and their effect on platelet numbers and mesenchymal stromal behavior in vitro. Stem Cells Int. 2016;2016:7414036.
Dhurat R, Sukesh M. Principles and methods of preparation of platelet-rich plasma: a review of author’s perspective. J Cutan Asthetic Surg. 2014;7(4):189–97.
Smith J, Finnoff JT. Diagnostic and interventional musculoskeletal ultrasound: part 1. Fundamentals PM & R. 2009;1(1):64–75.
Krobbuaban B, Diregpoke S, Prasan S, et al. Alcohol-based chlorhexidine vs. povidine iodine in reducing skin colonization prior to regional anesthesia procedure. J Med Assoc Thail. 2011;41(11):807–12.
Nazarian L, et al. AIUM practice guidelines for the performance of the musculoskeletal ultrasound examination. AIUM Practice Guidelines. 2007; 1–13.
Baima J, Isaac Z. Clean versus sterile technique for common joint injection: a review from the physiatry perspective. Curr Rev Musculoskelet Med. 2008;1:88–91.
Cohnheim J. Ueber entzu ndung und eiterung. Arch fu’r Pathol Anat und Physiol und fu’r Klin Med. 1867;40:1–79.
Murphy MB, Terrazas JA, Buford DA. Bone marrow concentrate and platelet-rich plasma acquisition and preparation. Tech Reg Anesth Pain Manag. 2015;19(1,2):19–25.
Friedenstein AJ, Chailakhyan RK, Latsinik NV, et al. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplatation. 1974;17(4):331–40.
Golpanian S, El-Khorazaty Y, Mendizabal A, DiFede DL, Suncion VY, Karantalis V, Fishman JE, Ghersin E, Balkan W, Hare JM. Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients. J Am Coll Cardiol. 2015;65(2):125–32.
Civin CI, Strauss LC, Brovali C, Fackler MJ, Schwartz JF, Shaper JH. Antigenic analysis of hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol. 1984;133(1):156–65.
Tindle RW, Nichols RA, Chan I, et al. A novel monoclonal antibody BI-3C5 recognises myeloblasts and non-B non-T lymphoblasts in acute leukemias and CGL blasts crises, and reacts with immature cells in normal bone marrow. Leuk Res. 1985;9(1):1–9.
Thomas ED, Storb R, Cliff RA, et al. Bone-marrow transplantation. N Engl J Med. 1975;292(17):895–902.
Phillips RL, Reinhart AJ, Van Zant G. Genetic control of murine hematopoietic stem cell pool sizes and cycling kinetics. Proc Natl Acad Sci U S A. 1992;89:11607–11.
Landsdorp PM, Dragowska W, Mayani H. Ontogeny-related changes in proliferative potential of human hematopoietic cells. J Exp Med. 1993;178:787–91.
Nygren JM, Bryder D, Jacobsen SE. Prolonged cell cycle transit is a defining and developmentally conserved hemopoietic stem cell property. J Immunol. 2006;177:201–8.
Kim MJ, Kim MH, Kim SA, Chang JS. Age-related deterioration of hematopoietic stem cells. Int J Stem Cells. 2008;1(1):55–63.
Murphy MB, Moncivas K, Kaplan AI. Mesenchymal stem cells environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 2013;45(11):e54.
Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9(5):641–50.
Horwitz EM, Andreef M, Frassoni F. Mesenchymal stromal cells. Curr Opin Hematol. 2006;13(6):419–25.
Friedenstein AK, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3(4):393–403.
Horwitz E, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy. 2005;7:393–5.
Finnoff JT. Regenerative rehabilitative medicine for joints and muscles. Curr PM & R Rep. 2020;8:8–16.
Salamanna F, Contartese D, Aldini NN, Brodano GB, Griffoni C, Gasbarrini A, Fini M. Bone marrow aspirate clot: a technical complication or a smart approach for musculoskeletal regeneration? J Cell Physiol. 2018;233:2723–32.
Hyer CF, Berlet GC, Bussewitz BW, Hankins T, Ziegler HL, Philbin TM. Quantitative assessment of the yield of osteoblastic connective tissue progenitors in bone marrow aspirate from iliac crest, tibia and calcaneus. J Bone Joint Surg Am. 2013;95:1312–6.
Iman MA, Mahmoud SSS, Holton J, Abouelmaati D, Elsherbini Y, Snow M. A systematic review of the concept and clinical applications of bone marrow aspirate concentrate in orthopedics. SICOT J. 2017;17(3):1–8.
Marx RE, Tursun R. A qualitative and quantitative analysis of autologous human multipotent adult stem cells derived from three anatomic areas by marrow aspiration: tibia, anterior ilium and posterior ilium. Int J Oral Maxillofac Implants. 2013;28(5):e290–4.
Fennema EM, Renard AJS, Leusink A, et al. The effect of bone marrow aspiration strategy on the yield and quality of human mesenchymal stem cells. Acta Orthop. 2009;80(5):618–21.
Muschler GF, Boehm C, Easley K. Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume. J Bone Joint Surg Am. 1997;79(11):1699–709.
Batinic D, Marusic M, Pavletic Z, et al. Relationship between differing volumes of bone marrow aspirates and their cellular composition. Bone Marrow Transplant. 1990;6(2):103–7.
Ehringer A, Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J Exp Med. 2011;208(3):421–8.
Scarpone M, Kuebler D, Harrell DB. Marrow cellution bone marrow aspiration system and related concentrations of stem and progenitor cells. Allegheny Health Network Annual Orthopedic Update. 2016;8-10.
Lamagna C, Bergers G. The bone marrow constitutes a reservoir of pericytes progenitors. J LeoKoc Biol. 2006;80(4):677–81.
Caplan AI. All MSCs are pericytes? Cell Stem Cell. 2008;3(3):229–30.
Hong SJ, Traktuev DO. Therapeutic potential of adipose-derived stem cells in vascular growth and tissue repair. Curr Opin Organ Transplant. 2010;15:86–91.
Kuhl T, Mezger M, Hausser I, et al. High local concentrations of intradermal MSCs restore skin integrity and facilitate wound healing in dystrophic epidermolysis bullosa. Mol Ther. 2015;23:1368–79.
Peng H, Huard J. Muscle-derived stem cells for musculoskeletal tissue regeneration and repair. Transpl Immunol. 2004;12:311–9.
Wang Y, Yu X, Chen E, et al. Liver-derived human mesenchymal stem cells: a novel therapeutic source for liver diseases. Stem Cell Res Ther. 2016;7:71.
Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3:301–13.
Caplan AI. New MSCs: MSCs as pericytes are sentinels and gatekeepers. J Orthop Res. 2017;35:1151–9.
Murray IR, Peault B. Q & A: mesenchymal stem cells—where do they come from and is it important? BMC Biol. 2015;13:99.
Baily JE, Chen WC, Khan N, et al. Isolation of perivascular multipotent precursor cell populations from human cardiac tissue. J Vis Exp. 2016;116:e54252.
Esteves CL, Donadeu FX. Pericytes and their potential in regenerative medicine across species. Cytometry. 2018;93(1):50–9.
Gokcinar-Yagci B, Uckan-Cetinkaya D, Celebi-Saltik B. Pericytes: properties, functions and applications in tissue engineering. Stem Cell Rev Rep. 2015;11(4):549–59.
Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8(4):315–7.
Bowen JE. Technical issues in harvesting and concentrating stem cells (bone marrow and adipose). PM & R. 2015;7(4 suppl):S8–S18.
Van Esch RW, Kool MM, van As S. NSAIDs can have adverse effects on bone healing. Med Hypothesis. 2003;81(2):343–6.
Kitajama M, Shigematsu M, Ogawa K, Sugihara H, Hotokebuchi T. Effect of glucocorticoid on adipocyte size in human bone marrow. Med Mol Morphol. 2007;40:150–6.
Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159(9):941–55.
Ramos FJ, Kaeberlein M. A healthy diet for stem cells. Nature. Jun 2012;486:477–8.
Wilkinson AC, Yamazaki S. Hematopoietic stem cell diet. Int J of Hematol. 2018;107:634–41.
Mana MD, Kuo EY, Yilmaz OH. Dietary regulation of adult stem cells. Curr Stem Cell Rep. 2017;3:1–8.
Sittitavornwong S, Falconer DS, Shah R, et al. Anatomic considerations for posterior superior iliac crest bone procurement. J Oral Maxillofac Surg. 2013;71:1777–88.
Hernigou J, Picard L, Alves A, Silvera J, Homma Y. Understanding bone safety zones during bone marrow aspiration from the iliac crest: the sector rule. Int Orthop. 2014;38(11):2377–84.
Hernigou J, Alves A, Homma Y, Guissou I, Hernigou P. Anatomy of the ilium for bone marrow aspiration: map of sectors and implication for safe trocar placement. Int Orthop. 2014;38(12):2585–90.
Gronkjaer M, Hasselgren CF, Ostergaerd AS, Johansen P, Korup J, Bogsted M, Bilgrau AE, Jensen P. Bone marrow aspiration: a randomized controlled trial assessing the quality of bone marrow specimens using slow and rapid aspiration techniques and evaluating pain intensity. Acta Haematol. 2016;135(2):81–7.
Vanhelleputte P, Nijs K, Delforge M, Evers G, Vanderschueren S. Pain during bone marrow aspiration: prevalence and prevention. J Pain Symptom Manag. 2003;26(3):860–6.
Malanga GA, Ibrahim V (eds). Regenerative treatments in sports and orthopedic medicine. Springer Publishing Company; 2017.
Zehnder JL, Schrier S, Rosmarin AG. Bone marrow aspiration and biopsy: indications and technique. Website: http://www.uptodate.com/contents/bone-marrowaspiration-and-biopsy-indication-and-tec... 2011.
Melampati S, Joshi S, Lai S, Braner DAV, Tegtmeyer K. Bone marrow aspiration and biopsy. N Engl J Med. 2009;361:e28.
Miller HJ, Awad SS, Crosby CT, et al. Chlorhexidine-alcohol versus povidone-iodine for surgical site antisepsis. N Engl J Med. 2010;362:18–26.
Friedlis MF, Centeno CJ. Performing a better bone marrow aspiration. Phys Med Rehabil Clin N Am. 2016;27:919–39.
Rahnama R, Wang M, Dang AC, et al. Cytotoxicity of local anesthetics on human mesenchymal stem cells. J Bone Jt Surg. 2013;95(2):132–7.
Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol. 2009;217(2):318–24.
Hernigou P, Matthieu G, Poignard A, et al. Percutaneous autologous bone marrow grafting for nonunions: surgical technique. J Bone Joint Surg Am. 2006;88(suppl 1):322–7.
Hernigou P, Homma Y, Flouzat Lachaniette CH, et al. Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cells. Int Orthop. 2013;37(11):2279–87.
Glass GE, Ferretti P. Adipose-derived stem cells in aesthetic surgery. Aesth Surg J. 2019;39(4):423–38.
Salgado AJBOG, Reis RLG, Sousa NJC, Gimble JM. Adipose tissue derived stem cells secretome: soluble factors and their roles in regenerative medicine. Curr Stem Cell Res Ther. 2010;5(2):103–10.
Arshad Z, Halioua-Haubold C, Roberts M, Fulvio U, Branford OA, Brindley DA, Davies BM, Pettitt D. Adipose-derived stem cells in asthetic surgery: a mixed methods evaluation of the current clinical trial, intellectual property, and regulatory landscape. Aesth Surg J. 2018;38(2):199–210.
Zollino I, Zuolo M, Gianesini S, Pedriali M, Sibilla MG, Tessari M, Carinci F, Occhionorelli S, Zamboni P. Autologous adipose-derived stem cells: basic science, technique, and rationale for application in ulcer and wound healing. Phlebol. 2017;32(3):160–71.
Nicoletti GF, De Francesco F, D’Andrea F, Ferraro GA. Methods and procedures in adipose stem cells: state of the art perspective for translational medicine. J Cell Physiol. 2015;230(4):489–95.
Kokai L, Traktuev D, Zhang L, Merfeld-Clauss S, DiBernardo G, Lu H, Marra K, Donnenberg A, Donnenberg V, Meyer E, Fodor P, March K, Rubin J. Adipose stem cell function maintained with age: an intra-subject study of long-term cryopreserved cells. Aesthet Surg J. 2017;37(4):454–63.
Bourin P, Bunnell BA, Casteilla L, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal /stem cells: a joint statement of the International Federation fir Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy. 2013;15(6):641–8.
De Ugarte DA, Alfonso Z, Zuk PA, et al. Differential expression of stem cell mobilization associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunol Lett. 2003;89(2–3):267–70.
Mitchell JB, McIntosh K, Zvonic S, et al. Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem-cell associated markers. Stem Cells. 2006;24(2):376–85.
Kern S, Eicher H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood or adipose tissue. Stem Cells. 2006;24(5):1294–301.
Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res. 2007;100(9):1249–60.
Contributors V. (Brousseau Z.) Fundamentals of US Regulatory Affairs, 10th Ed. Rockville: Regulatory Affairs Professionals Society. 2017.
Rodbell M, Jones AB. J Biol Chem. 1966;241:40–142.
Bunnell BA, Flaat M, Gagliardi C, Patel B, Ripoll C. Adipose-derived stem cells: isolation, expansion and differentiation. Methods. 2008;45(2):115–20.
Bjorntorp P, Karlsson H, Pertoft H, Pettersson P, Sjostrom U, Smith U. J Lipid Res. 1978;19(1978):316–24.
Padoin AV, Braga-Silva J, Martins P, et al. Sources of processed lipoaspirate cells: influence of donot site on cell concentration. Plast Reconstr Surg. 2008;122(2):614–8.
Lim AA, Fan K, Allam KA, et al. Autologous fat transplantation in the craniofacial patient: the UCLA experience. J Craniofac Surg. 2012;23(4):1061–6.
Choudhery MS, Badowski M, Muise A, et al. Subcutaneous adipose-derived stem cell utility is independent of anatomical harvest site. Biores Open Access. 2015;4(1):131–45.
Jurgens WJFM, et al. Effect of tissue harvesting site on yield of stem cells derived from adipose tissue: implications for cell-based therapies. Cell Tiss Res. 2008;323(3):415–26.
Klein JA. The tumescent technique: anesthesia and modified liposuction technique. Dermatol Clin. 1990;8:425–37.
Venkataram J. Tumescent liposuction: a review. J Cutan Aesth Surg. 2008;1(2):49–57.
Trivisonno A, Di Rocco G, Cannistra C, Finocchi V, Farr ST, Monti M, Toietta G. Harvest of superficial layers of fat with a microcannula and isolation of adipose tissue-derived stromal and vascular cells. Aesthe Surg J. 2014;34(4):601–13.
Doi K, Tanaka S, Lida H, et al. Stromal vascular fraction isolated from lipo-aspirates using an automated processing system: bench and bed analysis. J Tissue Eng Regen Med. 2012;7(11):864–70.
Aronowitz J, Lockhart R, Hakakian C, Birnbaum Z. Adipose-derived vascular fraction isolation. Ann Plastic Surg. 2016;77(3):354–62.
Van Dongen J, Harmsen M, Stevens H. Isolation of stromal vascular fraction by fractionation of adipose tissue. Methods Mol Biol. 1993;2020:91–103.
Tremolada C, Colombo V, Ventura C. Adipose tissue and mesenchymal stem cells: state of the art and Lipogems® technology development. Curr Stem Cell Rep. 2016;2(3):304–12.
Teimourian B, Rogers WB. A national survey of complications associated with suction lipectomy: a comparative study. Plast Reconstr Surg. 1989;84:628.
Ezzeddine H, Husari A, Nassar H, Kanso M, El Nounou G, Khalife M, Faraj W. Life threatening complications post-liposuction. Aesth Plast Surg. 2018;42:384–7.
Grazer FM, de Jong RH. Fatal outcomes from liposuction: census survey of cosmetic surgeons. Plast Reconstr Surg. 2000;105(1):436–46.
Coldiron B, Coleman W, Cox SE, Jacob C, Lawrence N, Kaminer M, Narins RS. ASDS guidelines of care for tumescent liposuction. Liposuction Council Bull Dermatol Surg. 2006;32:709–16.
Boni R. Safety of tumescent liposuction compared with liposuction in systemic sedation or general anesthesia—a review of the literature. Am J Cosm Surg. 2007;24(3):139–42.
Klein JA, Jeske DR. Estimated maximal safe dosages of tumescent lidocaine. Anesth Analg. 2016;122(5):1350–9.
Klein JA. Tumescent technique for regional anesthesia permits lidocaine doses of 35 mg/kg for liposuction. J Dermatol Surg Oncol. 1990;16:248–63.
Shoshani O, Berger J, Fodor L, et al. The effect of lidocaine and adrenaline on the viability of injected adipose tissue: an experimental study in nude mice. J Drugs Dermatol. 2005;4(3):311–6.
Keck M, Zeyda M, Gollinger K, et al. Local anesthetics have a major impact on viability of preadipocytes and their differentiation into adipocytes. Plast Reconstr Surg. 2010;126(5):1500–5.
Tapon-Bretaudiere J, Bros A, Couture-Tose E, Delain E. Electron microscopy of the conformational changes of alpha-2-macroglobulin from human plasma. EMBO J. 1985;4(1):85–9.
De Castro JC. Alpha-2-macroglobulin: the new weapon for neuropathic pains. J Anesth Pain Relief Manag. 2019; https://doi.org/10.31579/JAPM.2019/002.
Rehman AA, Khan FH, Ahsan H. Alpha-2 macroglobulin: a physiological guardian. J Cell Physiol. 2013;228:16651675.
Ritchie R, Palomaki G, Neveux L, Navolotskaia O, Ledue T, Craig W. Reference distributions for alpha 2-macroglobulin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Analy. 2004;18(2):139–47.
Becker C, Harpel P. Alpha-2-macroglobulin on human vascular endothelium. J Exp Med. 1976;144(1):1–9.
Sottrup-Jensen L. In the plasma proteins. Academic Press. 1987;5:192–291.
Garcia-Ferrer I, Marrero A, Gomis-Ruth FX, Goulas T. Alpha-2-macroglobulins: structure and function. Subcell Biochem. 2017;83:149–83.
Cuellar JM, Cuellar VG, Gabrovsky V, Scuderi GJ. Alpha-2-macroglobulin: autologous protease inhibition technology. PM & R Clin N Am. 2016;27(4):9098–918.
Arandjelovic S, Dragojlovic N, Li X, Myers RR, Campana WM, Gonias SL. A derivative of the plasma protease inhibitor Alpha-2-macroglobulin regulates the response to peripheral nerve injury. J Neurochem. 2007;103(2):694–705.
Orhurhu V, Schwartz R, Potts J, Peck J, Urits I, Orhurhu MS, Odonkor C, Viswanath O, Kaye AD, Gill J. Role of alpha-2-macroglobulin in the treatment of osteoarthritic knee pain: a brief review of the literature. Curr Pain Headache Rep. 2020;24(3):9.
Li S, Xiang C, Wei X, Sun X, Li R, Li P, Sun J, Wei D, Chen Y, Zhang Y, Wei L. Early supplemental α2-macroglobulin attenuates cartilage and bone damage by inhibiting inflammation in collagen-II induced arthritis model. Int J Rheuma Dis. 2019;22(4):654–65.
Huang B, Chen J, Zhang X, Wang J, Zheng Z, Shan Z, Liu J, Zhu Z, Zhao F. Alpha-2-macroglobulin as dual regulator for both anabolism and catabolism in the cartilaginous endplate of intervertebral disc. Spine (Phila Pa 1976). 2019;44(6):E338–47.
Vincenzetti S, Pucciarelli S, Huang Y, Ricciutelli M, Lambertucci C, Volpini R, Scuppa G, Soverchia L, Ubaldi M, Polzonetti V. Biomarkers mapping of neuropathic pain in a nerve chronic constriction injury mice model. Biochimie. 2019;158:172–9.
Liu Y, Cao W, Kong X, Li J, Chen X, Ge Y, Zhong W, Fang S. Protective effects of α-2-macroglobulin on human bone marrow mesenchymal stem cells in radiation injury. Mol Med Rep. 2018;18(5):4219–28.
Myers RR, Sekiguchi Y, Kikuchi S, Scott B, Medicherla S, Protter A, Campana WM. Inhibition of p38 MAP kinase activity enhances axonal regeneration. Exp Neurol. 2003;184:606–14.
Nadeau S, Fillali M, Zhang J, Kerr BJ, Rivest S, Vaccari JPR, Keane RW, Lacroix S. Functional recovery after peripheral nerve injury is dependent on the proinflammatory cytokines IL-1β and TNF: implications for neuropathic pain. J Neurosc. 2011;31-35:12533–42.
Wagner R, Myers RR. Endoneurial injection of TNF-α produces neuropathic pain behaviours. Neuroreport. 1996;7:2867–901.
Taskinen HS, Olsson T, Bucht A, Khademi M, Svelander L, et al. Peripheral nerve injury induces endoneurial expression of IFN-γ, IL-10, TNF-α, mRNA. J Neuroimmunol. 2000;102:17–25.
Shamash S, Reichert F, Rotschenker S. The cytokine network of Wallerian degeneration: tumor necrosis factor-α, interleukin-1α, and interleukin-1β. J Neurosci. 2002;22:3052–60.
Menge T, Jander S, Stoll G. Induction of the pro-inflammatory cytokine interleukin-18 by axonal injury. J Neurosci. 2001;65:332–9.
Reichert F, Levitzky R, Rotshenker S. Interleukin-6 in intact and injured mouse peripheral nerves. Eur J Neurosci. 1996;8:530–5.
Myers RR, Campana WM, Shubayev VL. The role of neuroinflammation in neuropathic pain; mechanisms and therapeutic targets. Drugs Disc Today. 2006;11:8–20.
Dubovy P. Wallerian degeneration and peripheral nerve conditions for both axonal regeneration and neuropathic pain induction. Ann Anat. 2011;193(4):267–75.
LaMarre J, Wollenberg GK, Gonias SL, Hayes MA. Cytokine binding and clearance properties of proteinase-activated α2-macroglobulins. Lab Investig. 1991;65(1):3–14.
Webb DJ, Gonias SL. A modified human alpha-2-macroglobulin derivative that binds tumor necrosis factor-alpha and interleukin-1 beta with high affinity in vitro and reverses lipopolysaccharide toxicity in vivo in mice. Lab Investig. 1998;78:939–48.
Gonias SL, Pizzo SV. Altered clearance of human alpha-2-macroglobulin complexes following reaction with cis-dichlorodiamineplatinum(II). Biochem Biophys Acta. 1981;678:268–74.
Benito MJ, Veale DJ, Fitzgerald O, van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheuma Dis. 2005;64:1263–7.
Todhunter PG, Kincaid SA, Todhunter RJ, Kammerman JR, Johnstone B, Baird AN, Hanson RR, Wright JM, Lin HC, Purohit RC. Immunohistochemical analysis of an equine model of synovitis-induced arthritis. Am J Vet Res. 1996;57:1080–93.
Lefebvre V, Pefers-Joris C, Vaes G. Modulation by interleukin 1 and tumor necrosis factor alpha of production of collagenase, tissue inhibitor of metalloproteinases and collagen types in differentiated and dedifferentiated articular chondrocytes. Biochim Biophys Acta. 1990;1052(3):366–78.
Clegg PD, Burke RM, Coughlan AR, Riggs CM, Carter SD. Characteristics of equine matrix metalloproteinase 2 and 9 and identification of the cellular sources of these enzymes in joints. Equine Vet J. 1997a;29:335–42.
Sutton S, Clutterbuck A, Harris P, Gent T, Freeman S, Foster N, Barrett-Jolly R, Mobasheri A. The contribution of the synovium, synovial derived inflammatory cytokines and neuropeptides to the pathogenesis of osteoarthritis. Vet J. 2009;179(1):10–24.
Ohtori S, Inoue G, Miyagi M, et al. Pathomechanisms of discogenic low back pain in humans and animal models. Spine J. 2015;15(6):1347–55.
Saal J, Saal JS. Nonoperative treatment of herniated lumbar intervertebral disc with radiculopathy: an outcome study. Spine (Phila Pa 1976). 1989;14:431–7.
Tetlow LC, Adlam DJ, Wooley DE. Matrix metalloproteinases and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum. 2001;44(3):585–94.
Baker JF, Walsh PM, Byrne DP, Mulhall KJ. Pravastatin suppresses matrix metalloproteinase expression and activity in human articular chondrocytes stimulated by interkeukin-1β. J Orthop Traumatol. 2012;13(3):119–23.
Garnero P, Landewe R, Chapurlat RD. The role of biochemical markers of joint tissue remodeling to predict progression and treatment efficacy in inflammatory rheumatic diseases. Rheuma. 2020;0:1–11.
Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev. 2011;7(1):33–42.
Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10(1):45–65.
Huang T, Wu C, Yu J, Sumi S, Yang K. I-lysine regulates tumor necrosis factor-alpha and matrix metalloproteinases-3 expression in human osteoarthritic chondrocytes. Process Biochem. 2016;51(7):904–11.
Larsson S, Englund M, Struglics A, Lohmander LS. Interleukin-6 and tumor necrosis factor alpha in synovial fluid are associated with progression of radiographic knee osteoarthritis in subjects with previous meniscectomy. Osteoarth Cart. 2015;23:1906–14.
Schulze-Tanzil G, Al-Sadi O, Wiegand E, et al. The role of proinflammatory and immunoregulatory cytokines in tendon healing and rupture: new insights. Scand J Med Sci Sports. 2011;21:337–51.
Chen W, Jin G, Xiong Y, Hu P, Bao J, Wu L. Rosmarinic acid down-regulated=s NO and PGE2 expression via MAPK pathway in rat chondrocytes. J Cell Mol Med. 2018;22(1):346–53.
Asghar S, Litherland GJ, Lockhart JC, Goodyear CS, Crilly A. Exosomes in intercellular communication and implications for osteoarthritis. Rheuma. 2020;59(1):57–68.
Goldring SR, Goldring MB. Clinical aspects, pathology and pathophysiology of osteoarthritis. J Musculoskelet Neuronal Interact. 2006;6:376–8.
Zhang S, Chuah SJ, Lai RC, et al. MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity. Biomaterials. 2018;156:16–27.
Wang S, Wei X, Zhou J, Zhang J, Li K, Chen Q, Terek R, Fleming BC, Goldring MB, Ehrlich MG, Zhang G, Wei L. Identification of α2-macroglobulin as a master inhibitor of cartilage-degrading factors that attenuates the progression of posttraumatic osteoarthritis. Arthritis Rheumatol. 2014;66(7):1843–53.
Tortorella MD, Arner EC, Hills R, Easton A, Korte-Sarfaty J, Fok K, et al. α2-macroglobulin is a novel substrate for ADAMTS-5 and represents and endogenous inhibitor of these enzymes. J Biol Chem. 2004;279:7554–61.
Luan Y, Kong L, Howell DR, Ilalov K, Fajardo M, Bai XH, et al. Inhibition of ADAMTS-7 and ADAMTS-12 degradation of cartilage oligomeric matrix protein by α2-macroglobulin. Osteoarthr Cartil. 2008;16:1413–20.
Kang JD, Georgescu HI, McIntyre-Larkin L, et al. Herniated lumbar intervertebral discs spontaneously produced matrix metalloproteinases, nitric oxide, interleukin-6 and prostaglandin-E2. Spine. 1996;21:271–7.
Smith MW, Ith A, Carragee EJ, Cheng I, Alamin TF, Golish SR, Mitsunaga K, Scuderi GJ, Smuck M. Does the presence of the fibronectin-aggrecan complex predict outcomes from lumbar discectomy for disc herniation? Spine J. 2019;19(2):e28–33.
Lynch TS, O’Connor M, Minkara AA. Biomarkers for femoroacetabular impingement and hip osteoarthritis. Am J Sports Med. 2019;47(9):2242–50.
Zhang Y, Wei X, Browning S, Scuderi G, Hanna LS, Wei L. Targeted designed variants of alpha-2-macroglobulin attenuate cartilage degeneration in a rat model of osteoarthritis induced by anterior cruciate ligament transection. Arthritis Res Ther. 2017;19:75.
Latypov RF, Harvey TS, Liu D, Bondarenko PV, Kohno T, Fachini RA II, Rosenfield RD, Ketchem RR, Brems DN, Raibekas AA. Biophysical characterization of structural proteins and folding of interleukin-1 receptor antagonist. J Mol Biol. 2007;368:1187–201.
Eisenberg SP, Evans RJ, Arend WP, Verderber E, Brewer MT, Hannum CH, Thompson RC. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature. 1990;343:341–6.
Thierry L, Vittecoq O, le Loet X. What is role of interleukin-1 receptor antagonist in rheumatic disease? Joint Bone Spine. 2007;74(3):223–6.
Dinarello CA, Thompson RC. Blocking IL-1: interleukin-1 receptor antagonist in vivo and in vitro. Immunol Today. 1991;12(11):4040–410.
Corradi A, Bajetto A, Cozzolino F, Rubartelli A. Production and secretion of interleukin-1 receptor antagonist in monocytes and keratinocytes. Cytotechnology. 1993;11:S50–2.
Bresnihan B. The safety and efficacy of interleukin-receptor antagonist in the treatment of rheumatoid arthritis. Sem Arthritis Rheuma. 2001;30(5):17–20.
Vittecoq O, Jacquot S, Jouen-Beades F, Pouplin S, Thomas M, Dutot I, et al. Potential diagnostic value of IL-1RA production by whole blood cells from community-recruited patients with very early arthritis. Results of the VErA study. Arthritis Rheuma. 2003;48(Suppl):542.
O’Shaughnessey K, Matuska A, Hoeppner J, et al. Autologous protein solution prepared from the blood of osteoarthritic patients contains an enhanced profile of anti-ibflammatory cytokines and anabolic growth factors. J Orthop Res. 2014;32(10):1349–55.
Ghivizzani S, Gouze E, Watson R, Saran J, Kay K, Bush M, Levings P, Gouze J. Interleukin-1 in rheumatoid arthritis: its inhibition by interleukin-1Ra and Anakinra. J Pharm Tech. 2007;23(2):86–94.
Sims JE, Gayle MA, Slack JL, et al. Interleukin-1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci U S A. 1993;90:6155–9.
Wesche H, Korherr C, Kracht M, Falk W, Resch K, Martin MU. The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J Biol Chem. 1997;272:7727–31.
Colotta F, Dower SK, Sims JE, Montovani A. The type II ‘decoy’ receptor: a novel regulatory pathway for interleukin-1. Immunol Today. 1994;15:562–6.
Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095–147.
Gouze JN, Gouze E, Palmer GD, et al. A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer. Arthritis Res Ther. 2003;5:301–9.
Evans CH, Chevalier X, Wehling P. Autologous conditioned serum. Phys Med Rehabil Clin N Am. 2016;27:893–908.
Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheuma. 1998;41:2196–204.
Schiff M. Durability and rapidity of response to anakinra in patients with rheumatoid arthritis. Drugs. 2012;64(22):2493–501.
Fleischman R, Schechtman J, Bennett R, Handel M, Burmester G, Tesser J, Modafferi D, Poulakos J, Sun G. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHulL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheuma. 2003;48(4):927–34.
Dinesh P, Rasool M. Multifaceted role of interleukin-21 in rheumatoid arthritis: current understanding and future perspective. J Cell Physiol. 2018;233(5):3918–28.
Chevalier X, Giraudeau B, Conrozier T, et al. Safety study of intraarticular injection of interleukin-1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol. 2005;32:1317–23.
Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009;61:344–52.
Bacconnier L, Jorgensen C, Fabre S. Erosive osteoarthritis of the hand: clinical experience with anakinra. Ann Rheum Dis. 2009;68:1078–9.
Cavalli G, Dinarello C. Treating rheumatological diseases and comorbidities with interleukin-1 blocking therapies. Rheumatology. 2015;54(12):2134–44.
Magalon J, Bausset O, Veran J, Giraudo L, Serratrice N, Magalon G, Dignat-George F, Sabatier F. Physico-chemical factors influencing autologous conditioned serum purification. Biores Open Access. 2014;3(1):35–8.
Arend WP, Leung DY. IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev. 1994;139:71–8.
Meijer H, Reinecke J, Becker C, Tholen G, Wehling P. The production of anti-inflammatory cytokines in whole blood by physico-chemical induction. Inflamm Res. 2003;52:404–7.
Granowitz EV, Clark BD, Mancilla J, Dinarello CA. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem. 1991;266:14147–50.
Wehling P, Moser C, Frisbie D, et al. Autologous conditioned serum in the treatment of orthopedic diseases: the orthokine therapy. BioDrugs. 2007;21(5):323–32.
Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature. 1990;343:336–40.
Carter DB, Deibel MR Jr, Dunn CJ, et al. Purification, cloning, expression, and biological characterization of an interleukin-1 receptor antagonist protein. Nature. 1990;344:633–8.
Rutgers M, Saris DB, Dhert WJA, Creemers LB. Cytokine profile of autologous conditioned serum for treatment of osteoarthritis, in vitro effects on cartilage metabolism and intra-articular levels after injection. Arthritis Res Ther. 2010;12:R114.
Auw Yang KG, Raijmakers NJH, Van Arkel ERA, Caron JJ, Rijk PC, Willems WJ, et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthr Cartil. 2008;16:498–505.
Baltzer AWA, Moser C, Jansen SA, Krauspe R. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthr Cartil. 2009;17:152–60.
Zarringam D, Bekkers J, Saris D. Long term effect of injection treatment for osteoarthritis in the knee by Orthokin autologous conditioned serum. Cartilage. 2018;9(2):140–5.
Strumper R. Intraarticular injections of autologous conditioned serum to treat pain from meniscal lesions. Sports Med Int Open. 2017;1(6):E200–5.
Baselga GEJ, Miguel HTP. Treatment of osteoarthritis with a combination of autologous conditioned serum and physiotherapy: a two-year observational study. PLoS One. 2015;10(12):e0145551.
Wehling P, Evans C, Wehling J, Maixner W. Effectiveness of intraarticular therapies in osteoarthritis: a literature review. Therap Adv Musculoskel Dis. 2017;9(8):183–96.
Darabos N, Hundric-Haspl Z, Haspl M, Markotic A, Darabos A, Moser C. Correlation between synovial fluid and serum IL-1β levels after ACL surgery: a preliminary report. Int Orthop. 2008;33(2):413–8.
Cameron M, Buchgraber A, Passler H, Vogt M, Thonar E, Fu F, Evans CH. The natural history of anterior ligament deficient knee. Changes in synovial fluid cytokine and keratan sulfate concentrations. Am J Sports Med. 1997;25:751–4.
Marks P, Cameron M. Inflammatory cytokine profiles correlate with the degree of chondrosis in the chronic anterior cruciate ligament deficient knee. ACL study meeting. 2000; Rhodes, Greece.
Darabos N, Haspl M, Moser C, et al. Intraarticular application of autologous-conditioned serum (ACS) reduces bone tunnel widening after ACL reconstructive surgery in a randomized controlled trial. Knee Surg Sports Traumatol Arthrosc. 2011;19(Suppl):536–46.
Genc E, Beytemur O, Yuksel S, Eren Y, Caglar A, Kucukyildirim B, Gulec M. Investigation of the biomechanical and histopathological effects of autologous conditioned serum on healing of achilles tendon. Acta Orthop Traumatol Turc. 2018;52(3):226–31.
Muller S, Quirk N, Muller-Lebschi J, Heisterbach P, Durselen L, Majewski M, Evans C. Response of the injured tendon to growth factors in the presence or absence of paratenon. Am J Sports Med. 2019;47(2):462–7.
Majewski M, Ochsner PE, Liu F, et al. Accelerated healing of the rat Achilles tendon in response to autologous conditioned serum. Am J Sports Med. 2009;37(11):2117–25.
Goni VG, Singh Jhala S, Gopinathan NR, et al. Efficacy of epidural perineural injection of autologous conditioned serum in unilateral cervical radiculopathy: a pilot study. Spine. 2015;40:E915–21.
Becker C, Heidersdorf S, Drewlo S, de Rodriguez SZ, Kramer J, Wilburger RE. Efficacy of epidural injections with autologous conditioned serum for lumbar radicular compression: an investigator-initiated, prospective, double-blind, reference-controlled study. Spine. 2007;32:1803–8.
Ravi Kumar HS, Goni VG, Batra YK. Autologous conditioned serum as a novel alternative option in the treatment of unilateral lumbar radiculopathy: a prospective study. Asian Spine J. 2015;9:916–22.
Wright-Carpenter T, Klein P, Schaferhoff P, Appell H, Mir L, Wehling P. Treatment of muscle injuries by local administration by autologous conditioned serum: a pilot study on sportsmen with muscle strains. Int J Sports Med. 2005;25(8):588–93.
Wright-Carpenter T, Opolon P, Appell H, Meijer H, Wehling P, Mir L. Treatment of muscle injuries by local administration by autologous conditioned serum: animal experiments using a muscle contusion model. Int J Sports Med. 2005;25(8):582–7.
Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med. 2010;26(3):355–69.
Sakellariou V, Poultsides LA, Ma Y, et al. Risk assessment for chronic pain and patient satisfaction after total knee arthroplasty. Orthopedics. 2016;39(1):55–62.
Singh J. Epidemiology of knee and hip arthroplasty: a systematic review. Open Orthop J. 2011;5:80–5.
De Girolamo L, Kon E, Filardo G, Marmotti AG, Soler F, Peretti GM, Vannini F, Madry H, Chubinskaya S. Regenerative approaches for the treatment of early OA. Knee Surg Sports Traumatol Arthrosc. 2016;24:1826–35.
Crane DM, Oliver KS, Bayes MC. Orthobiologics and knee osteoarthritis: a recent literature review, treatment algorithm, and pathophysiology discussion. Phys Med Rehabil Clin N Am. 2016;27:985–1002.
Mascarenhas R, Saltzman B, Fortier L, et al. Role of platelet-rich plasma in articular cartilage injury and disease. J Knee Surg. 2014;28(1):3–10.
Block TJ, Garza JR. Regenerative cells for the management of osteoarthritis and joint disorders: a concise literature review. Aesth Surg J. 2017;37(53):S9–S15.
Chang KV, Hung CY, Aliwarga F, et al. Comparative effectiveness of platelet-rich plasma injections for treating knee joint cartilage degenerative pathology: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2014;95(3):562–75.
Riboh JC, Saltzman BM, Yanke AB, et al. Effect of leucocyte concentration on the efficacy of platelet-rich plasma in the treatment of knee osteoarthritis. Am J Sports Med. 2016;44(3):792–800.
Souzdalnitski D, Narouze S, Lerman I, Calodney A. Platelet-rich plasma injections for knee osteoarthritis: systematic review of duration of clinical benefits. Tech Reg Anesth Pain Manag. 2015;19(1):67–72.
Yan W, Xu X, Xu Q, Sun Z, Jiang Q, Shi D. Platelet-rich plasma in combination with injectable hyaluronic acid hydrogel for porcine cartilage regeneration: a 6-month follow-up. Regen Biomater. 2020;7(1):77–90.
Dallari D, Stagni C, Rani N, et al. Ultrasound-guided injection of platelet-rich plasma and hyaluronic acid, separately and in combination, for hip osteoarthritis: a randomized-controlled study. Am J Sports Med. 2016;44(3):664–71.
Singh JR, Haffey P, Valimahomed A, Gelhorn AC. The effectiveness of autologous platelet-rich plasma for osteoarthritis of the hip: a retrospective analysis. Pain Med. 2019;20(8):1611–8.
Zuk PAM, Zhu H, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz P, Hedrick H. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue. 2001;7:211–28.
Cho H, Kim H, Kim Y, Kim K. Recent clinical trials in adipose-derived stem cell-mediated osteoarthritis treatment. Biotechnol Bioproc. 2020;24(6):839–53.
Sun Y, Chen S, Pei M. Comparative advantages of infrapatellar fat pad: an emerging stem cell source for regenerative medicine. Rheumatology. 2018;57(12):2072–86.
Shapiro SA, Kazmerchak SE, Heckman MG, Zubair AC, O’Connor MI. A prospective, single-blind, placebo-controlled trial of bone marrow aspirate for knee osteoarthritis. Am J Sports Med. 2017;45(1):82–90.
Centeno C, Pitts J, Al-Sayegh H, Freeman M. Efficacy of autologous bone marrow concentrate for knee osteoarthritis with or without adipose graft. Biomed Res Int. 2014; 370621.
Law L, Hunt CL, Nassr A, Larson AN, Eldrige JS, Mauck WD, Pingree MJ, Yang J, Muir CW, Erwin PJ, Bydon M, Qu W. Office-based mesenchymal stem cell therapy for the treatment of musculoskeletal diseases: a systematic review of recent human studies. Pain Med. 2019;20(8):1570–83.
Tsaipalis D, Zeugolis D. Hypoxia preconditioning of bone marrow stem cells before implantation in orthopedics. Am J Orthop Surg. 2019;27(23):e1040–2.
Kokubo M, Sato M, Yamato M, Mitani G, Uchiyama Y, Mochida J, Okano T. Characterization of layered chondrocyte sheets created in a co-culture system with synviocytes in a hypoxic environment. J Tiss Eng Regen Med. 2017;11(10):2885–94.
Tiku ML, Sabaawy HE. Cartilage regeneration for treatment of osteoarthritis: a paradigm for non-surgical intervention. Ther Adv Musculoskel Dis. 2015;7(3):76–87.
Siddiqui AJ, Mazzola TJ, Shiple BJ. Techniques for performing regenerative procedures for orthopedic conditions. Regen Treat Sports Orthop Conditions. 2018:221–56.
Sharma P, Maffulli N, Maffulli N. Tendon structure biology of tendon injury: healing, modeling and remodeling. J Musculoskelet Neuronal Interact. 2006;6:181–90.
Sakabe T, Sakai T. Musculoskeletal diseases—tendon. Br Med Bull. 2011;99:211–25.
Chisari E, Rehak L, Khan WS, Maffulli N. Tendon healing in presence of chronic low-level inflammation: a systematic review. Br Med Bull. 2019;132:97–116.
Abate M, Gravare-Silbernagel K, Siljeholm C, et al. Pathogenesis of tendinopathies: inflammation or degeneration? Arthritis Res Ther. 2009;11:235.
Hammerman M, Blomgram P, Dansac A, et al. Different gene response to mechanical loading during early and late phases of rat Achilles tendon healing. J Appl Physiol. 2017;123:800–15.
Hammerman M, Dietrich-Zagonel F, Blomgran P, et al. Different mechanisms activated by mild versus strong loading in rat achilles tendon healing. PLoS One. 2018;13:e0201211.
Hammerman M, Aspenberg P, Eliasson P. Microtrauma stimulates rat Achilles tendon healing via an early gene expression pattern similar to mechanical loading. J Appl Phyiol. 2014;116:54–60.
Schepull T, Aspenberg P. Early controlled tension improves the material properties of healing human achilles tendon after ruptures: a randomized trial. Am J Sports Med. 2013;41:2550–7.
Rack P, Ross H. The tendon of flexor pollicis longus: its effect on the muscular control of force and position at the human thumb. J Physiol. 1984;351:99–110.
Bruns J, Kampen J, Kahrs J, Plitz W. Achilles tendon rupture: experimental results in spontaneous repair in a sheep-model. Knee Surg Sports Traumatol Arthrosc. 2000;8:364–9.
Geremia GM, Bobbert MF, Casa Nova M, Ott RD, Lemos Fde A, Lupion Rde O, et al. The structural and mechanical properties of the Achilles tendon 2 years after surgical repair. Clin Biomech (Bristol, Avon). 2015;30:485–92.
Brown MN, Shiple BJ, Scarpone M. Regenerative approaches to tendon and ligament conditions. Phys Med Rehabil Clin N Am. 2016;27:941–84.
Petersen W, Tillman B. Structure and vascularization of the cruciate ligaments of the human knee joint. Anat Embryol (Berl). 1999;200(3):325–44.
Robi K, Jakob N, Matevz K, Matjaz B. The physiology of sports injuries and repair processes. In: Hamlin M, Draper N, Kathiravel Y, editors. Current issues in sports and exercise medicine. London: IntechOpen; 2013.
Galatz L, Ball C, Teefey S, et al. The outcome and repair of integrity of completely arthroscopically repaired large and massive rotator cuff tears. J Bone Joint Surg Am. 2004;86:219–24.
Lim WL, Liau LL, Ng MH, Chowdhury SR, Law JX. Current progress in tendon and ligament tissue engineering. Tissue Eng Regen Med. 2019;16(6):549–71.
Fleming B, Hulstyn M, Oksendahl HL, et al. Ligament injury, reconstruction and osteoarthritis. Curr Opin Orthop. 2005;16(5):354–62.
Bosch G, Van Shie H, de Groot M, et al. Effects of platelet-rich plasma on the quality of repair of mechanically induced core lesions in equine superficial digital flexor tendons: a placebo-controlled experimental study. J Orthop Res. 2010;28:211–7.
Sanchez M, Albillos J, Angulo F, Santisteban J, Andia I. Platelet-rich plasma in muscle and tendon healing. Oper Tech Orthop. 2012;22(1):16–24.
Hurley ET, Lim Fat D, Moran CJ, Mullet H. The efficacy of platelet-rich plasma and platelet-rich fibrin in arthroscopic rotator cuff repair: a meta-analysis of randomized controlled trials. Am J Sports Med. 2019;47(3):753–61.
Liddle AD, Rodriguez-Merchan C. Platelet-rich plasma in the treatment of patellar tendinopathy: a systematic review. Am J Sports Med. 2015;43(10):2583–90.
Ben-Nafa W, Munro W. The effect of corticosteroid versus platelet-rich plasma injection therapies for the management of lateral epicondylitis: a systematic review. SICOT-J. 2018;4:11.
Mishra AK, Skrepnik NV, Edwards SG, Jones JL, Sampsons S, Vermillion DA, et al. Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multicenter, randomized controlled trial of 230 patients. Am J Sports Med. 2014;42(2):463–71.
Fitzpatrick J, Bulsara M, Zheng M. The effectiveness of platelet-rich plasma in the treatment of tendinopathy: a meta-analysis of randomized controlled clinical trial. Am J Sports Med. 2017;45(1):226–33.
Clark NJ, Desai VS, Dines JD, Morrey ME, Camp CL. Nonreconstruction options for treating medial ulnar collateral ligament of the elbow in overhead athletes. Curr Rev Musculosket Med. 2018;11(1):48–54.
Dines JS, Williams PN, ElAttrache N, Conte S, Ahmad CS, et al. Platelet-rich plasma can be used to successfully treat elbow ulnar collateral ligament insufficiency in high-level throwers. Am J Orthop. 2016;45(5):296–300.
Vogrin M, Rupreht M, Crnjac A, Dinevski D, Krajnc C, Recnik G. The effect of platelet-derived growth factors on stability after anterior cruciate ligament reconstruction: a prospective randomized clinical study. Wien Klin Wochenschrift. 2010;122(S2):91–5.
Di Matteo B, Loibl M, Andriolo L, et al. Biologic agents for anterior cruciate ligament healing: a systematic review. World J Orthop. 2016;7(9):592–603.
Walters B, Porter D, Hobart S, Bedford B, Hogan D, McHugh M, Klein D, Harousseau K, Nicholas S. Effect of intra-operative platelet-rich plasma treatment on post-operative donor site knee pain in patellar tendon autograft anterior cruciate ligament reconstruction: a double-blind randomized controlled trial. Am J Sports Med. 2018;46(8):1827–35.
Kia C, Baldino J, Bell R, Ramji A, Uyeki C, Mazzocca A. Platelet-rich plasma: review of current literature on its use for tendon and ligament pathology. Curr Rev Musculosket Med. 2018;11(4):566–72.
Leong N, Kator J, Clemens T, James A, Enamoto-Iwamoto M, Jiang J. Tendon and ligament healing and current approaches to tendon and ligament regeneration. J Orthop Res. 2020;38(1):7–12.
Fu Y, Karbaat L, Wu L, et al. Trophic effects of mesenchymal stem cells in tissue regeneration. Tissue Eng Part B Rev. 2017;23:515–28.
Walia B, Huang A. Tendon stem progenitor cells: understanding the biology to inform therapeutic strategies for tendon repair. J Orthop Res. 2019;37(6):1270–80.
Mautner K, Blazuk J. Where do injectable stem cell treatments apply in treatment of muscle, tendon and ligament injuries? PM & R. 2016;7(4 suppl):S33–40.
Mei-Dan O, Kots E, Barchilon V, et al. A dynamic ultrasound examination for the diagnosis of ankle syndesmotic injury in professional athletes. Am J Sports Med. 2009;37(5):1009–16.
Gutierrez M. Ultrasound-guided procedures in rheumatology: what is the evidence? J Clin Rheumatol. 2015;21(4):201–10.
Thain L, Adler R. Sonography of the rotator cuff and biceps tendon: technique, normal anatomy, and pathology. J Clin Ultrasound. 1999;27(8):446–58.
Malanga GA, Axtman M, Mautner KR. The rationale and evidence for performing ultrasound-guided injections. Atlas Ultrasound-guided Musculoskel Inject. 2014:18–22.
Wilson JJ, Lee KS, Chamberlain C, DeWall R, Baer GS, Greatens M, Kamps N. Intratendinous injections of platelet-rich plasma: feasibility and effect on tendon pathology and mechanics. J Exp Orthop. 2015;2(1):5.
Rossi LA, Romoli ARM, Altiere BAB, Flor JAB, Scordo WE, Elizondo CM. Does platelet-rich plasma decrease time to return to sports in acute muscle tear? A randomized controlled trial. Knee Surg Sports Traumatol Arthrosc. 2017;25:3319–25.
Ekstrand J, Hagglund M, Walden M. Epidemiology of muscle injuries in professional football (soccer). Am J Sports Med. 2011;39(6):1226–32.
Hallen A, Ekstrand J. Return to play following muscle injuries in professional footballers. J Sports Sci. 2014;32(13):1229–36.
Ahmad CS, Redler LH, Ciccotti MG, Maffuli N, Longo UG, Bradley J. Evaluation and management of hamstring injuries. Am J Sports Med. 2013;41(12):2933–47.
Wong S, Ning A, Lee C, Feeley B. Return to sports after muscle injury. Curr Rev Musculoskelet Med. 2015;8(2):168–75.
Boppart MD, De Lisio M, Zou K, Huntsman HD. Defining a role for non-satellite stem cells in the regulation of muscle repair following exercise. Front Physiol. 2013;4:310.
Motahashi N, Asakura A. Muscle satellite cell heterogeneity and self-renewal. Front Cell Dev Biol. 2014;2:1.
Karalaki M, Fili S, Philippou A, Koutsilieres M. Muscle regeneration: cellular and molecular events. In Vivo. 2009;23(5):779–96.
Perandini L, Chimin P, Lutkemeyer D, Camara N. Chronic inflammation in skeletal muscle impairs satellite cells function during regeneration: can physical exercise restore the satellite cell niche? Febs J. 2018;285(11):1973–84.
Yumiko O, Ichiro M. Macrophages in inflammation, repair and regeneration. Int Immunol. 2018;30:11.
Gilbert-Honick J, Grayson W. Vascularized and innervated skeletal muscle tissue engineering. Adv Healthc Mater. 2020;9(1):1–27.
Corona BT, Wenke JC, Ward CL. Cells Tissues Organs. 2016;202:180.
Yosef B, Zhou Y, Mouschouris K, Poteracki J, Soker S, Criswell T. N-acetyl-L-cysteine reduces fibrosis and improves muscle function after acute compartment syndrome injury. Military Med. 2020;185(Suppl1):25–34.
Amthor H, Nicolas G, McKinnell I, Kemp CF, Sharma M, Kambadur R, Patel K. Follistatin complexes myostatin and antagonizes myostatin-mediated inhibition of myogenesis. Dev Biol. 2004;270:19–30.
Wong A, Pomerantz J. The role of muscle stem cells in regeneration and recovery after denervation: a review. Plast Reconstr Surg. 2019;143(3):779–88.
Grassi A, Napoli F, Romandini I, Samuelsson K, Zaffagnini S, Candrian C, Filardo G. Is platelet-rich plasma (PRP) effective in the treatment of acute muscle injuries? A systematic review and meta-analysis. Sports Med. 2018;48(4):971–89.
Setayesh K, Villarreal A, Gottschalk A, Tokish J, Choate W. Treatment of muscle injuries with platelet-rich plasma: a review of the literature. Curr Rev Musculoskelet Med. 2018;11(4):635–42.
Ziegler C, Van Sloun R, Gonzalez S, Whitney K, DePhillipo N, Kennedy M, Dornan G, Evans T, Huard J, LaPrade R. Characterization of growth factors, cytokines and chemokines in bone marrow concentrate and platelet-rich plasma: a prospective analysis. Am J Sports Med. 2019;47(9):2174–87.
Gang EJ, Darabi R, Bosnakovski D, et al. Engraftment of mesenchymal stem cells into dystrophin-deficient mice is not accompanied by functional recovery. Exp Cell Res. 2009;315:2624–36.
Dunn A, Talovic M, Patel K, Patel A, Marcinczyk M, Garg K. Biomaterial and stem-cell based strategies for skeletal muscle regeneration. J Orthop Res. 2019;37(6):1246–62.
Hamid AM, Mohamed Ali MR, Yusof A, et al. Platelet- rich plasma injections for the treatment of hamstring injuries: a randomized controlled trial. Am J Sports Med. 2014;42(10):2410–8.
Park P, Cai C, Bawa P, Kumaravel M. Platelet-rich plasma vs. steroid injections for hamstring injury: is there really a choice? Skelet Radiol. 2018;48(4):577–82.
Arner J, Lawyer T, Mauro C, Bradley J. Platelet-rich plasma shortens return to play in National Football League (NFL) Players with acute hamstring injuries. Orthop J Sports Med. 2019;7(7 suppl 5):1.
Gaballah A, Elgeidi A, Bressel E, Shakrah N, Abd-Alghany A. Rehabilitation of hamstring strains: does a single injection of platelet-rich plasma improve outcomes? (Clinical Study). Sports Sci Health. 2018;14(2):439–47.
Manduca M, Straub S. Effectiveness of PRP injection in reducing recovery time of acute hamstring injury: a critically appraised topic. J Sport Rehabil. 2018;27(5):4870–484.
Hamilton B, Tol JL, Almusa E, et al. Platelet-rich plasma does not enhance return to play in hamstring injuries: a randomized controlled trial. Br J Sports Med. 2015;49(14):943–50.
Bradley JP, Lawyer TJ, Ruef S, Towers JD, Arner JW. Platelet-rich plasma shortens return to play in National Football League Players with acute hamstring injuries. Orthop J Sports Med. 2020;8(4):1–5.
Evangelidis P, Massey G, Ferguson R, Wheeler P, Pain M, Folland J. The functional significance of hamstrings composition: is it really a “fast” muscle group? Scand J Med Sci Sports. 2017;27(11):1181–9.
Bentzen R, Ma O, Herzka A. Point of care ultrasound diagnosis of proximal hamstring rupture. J Emerg Med. 2018;54(2):225–8.
Peterson J, Thorborg K, Nielsen M, Skjodt T, Bolvig L, Bang N, Holmich P. The diagnostic and prognostic value of ultrasonography in soccer players with acute hamstring injuries. Am J Sports Med. 2014;42(2):399–404.
Hall M. Return to play after thigh muscle injury: utility of serial ultrasound in guiding clinical progression. Curr Sports Med Rep. 2018;17(9):296–301.
Alzahrani M, Aldebeyan S, Abduljabbar F, Martineau P. Hamstring injuries in athletes: diagnosis and treatment. JBJS Rev. 2015;3(6):11.
Chu S, Rho M. Hamstring injuries in the athlete: diagnosis, treatment and return to play. Curr Sports Med Rep. 2016;15(3):184–90.
Kubrova E, van Wijnen A, Qu W. Spine disorders and regenerative rehabilitation. Curr Physical Med Rehabil Rep. 2020;8(1):30–6.
Sakai D, Andersson G. Stem cell therapy for intervertebral disk regeneration: obstacles and solutions. Nat Rev Rheumatol. 2015;11(4):243–56.
Hicks GE, Morone N, Weiner DK. Degenerative lumbar disk and facet disease in older adults: prevalence and clinical correlates. Spine (Phila Pa 1976). 2009;34(12):1301–6.
Theis KA, Roblin DW, Helmick CG, Luo R. Prevalence and cause of work disability among work-age US adults, 2011-2013. NHIS Disabil Health J. 2018;11(1):108–15.
Jensen TS, Albert HB, Soerensen JS, et al. Natural course of disc morphology in patients with sciatica: an MRI study using a standardized qualitative classification system. Spine (Phila Pa 1976). 2006;31(14):1606–12.
Sowa G. Using biology to define optimal treatments for low back pain opportunities for physiatrists. Am J Phys Med Rehabil. 2013;92(10):841–8.
Bogduk M. Clinical anatomy of the lumbar spine and sacrum. 4th ed. New York: Elsevier; 2005. p. 147–8.
Dowdell J, Erwin M, Choma T, Vaccaro A, Iatridis J, Cho SK. Intervertebral disk degeneration and repair. Neurosurgery. 2017;80(3S):S46–54.
Mascarinas A, Harrison J, Boachie-Adjie K, Lutz G. Regenerative treatments for spinal conditions. Phys Med Rehabil Clin N Am. 2016;27:1003–17.
Wang S, Chang Q, Lu J, Wang C. Growth factors and platelet-rich plasma: promising biological strategies for early intervertebral disc degeneration. Int Orthop. 2015;39(5):927–34.
Le Maitre CL, Richardson SM, Baird P, et al. Expression of receptors for putative anabolic growth factors in human intervertebral disc: implications for repair and regeneration of the disc. J Pathol. 2005;207:445–52.
Vadala G, Sowa G, Hubert M, Gilbertson L, Denaro V, Kang J. Mesenchymal stem cells injection in degenerated intervertebral disc: cell leakage may induce osteophyte formation. J Tiss Engg Regen Med. 2012;6(5):348–55.
Zhao L, Manchikanti L, Kaye A, Abd-Elsayed A. Treatment of discogenic low back pain: current treatment strategies and future options—a literature review. Curr Pain Headache Rep. 2019;23(11):1–9.
Livshits V, Popham M, Malkin I, et al. Lumbar disc degeneration and genetic factors are the main risk factors for low back pain in women: the UK twin spine study. Ann Rheum Dis. 2011;70(10):1740–5.
Kalichman L, Hunter DJ. The genetics of intervertebral disc degeneration. Familial disposition and heritability estimation. Joint Bone Spine. 2008;75(4):383–7.
Liuke M, Solovieva S, Lamminen A, et al. Disk degeneration of the lumbar spine in relation to overweight. Int J Obes. 2005;29(8):903–8.
Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. 2006;83(2):461S–5S.
Valimahomed A, Haffey P, Urman R, Kaye A, Yong R. Regenerative techniques for neuraxial back pain: a systematic review. Curr Pain Headache Rep. 2019;23(3):1–11.
Schwarzer AC, Aprill CN, Derby R, Fortin J, Kine G, Bogduk N. The prevalence and clinical features of internal disc disruption in patients with low back pain. Spine. 1995;20(17):1878–83.
Peng B, Fu X, Pang X, Li D, Liu W, Gao C, et al. Prospective clinical study on natural history of discogenic low back pain at 4 years of follow-up. Pain Physician. 2012;15:525–32.
Schol J, Sakai D. Cell therapy for intervertebral disc herniation and degenerative disc disease: clinical trials. Int Orthop. 2018;43(4):1011–25.
Nguyen TH, Randolph DC, Talmage J, Succop P, Travis R. Long term outcomes of lumbar fusion among workers’ compensation subjects: a historical cohort study. Spine. 2011;36(4):320–31.
Monfett M, Harrison J, Boachie-Adjei K, Lutz G. Intradiscal platelet-rich plasma (PRP) injections for discogenic low back pain: an update. Int Orthop. 2016;40(6):1321–8.
Burnham T, Conger A, Tate Q, Cushman D, Kendall R, Schneider B, McCormick Z. The effectiveness and safety of percutaneous platelet-rich plasma and bone marrow aspirate concentrate for the treatment of suspected of discogenic low back pain: a comprehensive review. Curr Phys Med Rehabil Rep. 2019;7(4):372–84.
Levi D, Horn S, Tyszko S, Levin J, Hecht-Leavitt C, Walko E. Intradiscal platelet-rich plasma injection for chronic discogenic low back pain: preliminary results from a prospective trial. Pain Med. 2016;17(6):1010–22.
Urits I, Viswanath O, Galasso A, Sottosani E, Mahan K, Aiudi C, Kaye A, Orhurhu V. Platelet-rich plasma for the treatment of low back pain: a comprehensive review. Curr Pain Headache Rep. 2019;23(7):1–11.
Singla B, Batra Y, Bharti N, Goni V, Marwaha N. Steroid versus platelet-rich plasma in ultrasound-guided sacroiliac joint injection for chronic low back pain. Pain Pract. 2017;17(6):782–91.
Pairuchvej S, Muljadi J, Arirachakaran A, Kongtharvonskul J. Efficacy of platelet-rich plasma in posterior lumbar interbody fusion: systematic review and meta-analysis. Eur J Orthop Surg Traumatol. 2020;30(4):583–93.
Kim H, Yeom J, Koh Y, Yeo J, Kang K, Kang Y, Chang B, Lee C. Anti-inflammatory effect of platelet-rich plasma on nucleus pulposus cells with response of TNF-α and IL-1. J Orthop Res. 2014;32(4):551–6.
Montesano PX, Cuellar JM, Scuderi GJ. Intradiscal injection of an autologous alpha-2-macroglobulin (A2M) concentrate alleviates back pain in FAC-positive patients. Orthop Rheumatol. 2017;4(2):555634.
Dimitroulas T, Lambe T, Raphael JH, Kitas GD, Duarte RV. Biologic drugs as analgesics for the management of low back pain and sciatica. Pain Med. 2019;20(9):1678–86.
Takahashi K, Ohtori S. Perspectives of treatment of low back pain. Glob Spine J. 2017;4(1_suppl):s-0034.
Ohtori S, Miyagi M, Inoue G. Sensory nerve ingrowth, cytokines, and instability of discogenic low back pain: a review. Spine Surg Relat Res. 2018;2(1):11–7.
Takahashi K, Aoki Y, Ohtori S. Resolving discogenic pain. Eur Spine J. 2008;17(4):428–31.
Ohtori S, Aoki Y, Orita S. Pain generators and pathways of degenerative disc disease. Lumbar Spine Online Textbook. JBJS. Section 2, Chapter 4. 2018.
Urits I, Capuco A, Sharma M, Kaye A, Viswanath O, Cornett E, Orhurhu V. Stem cell therapies for treatment of discogenic low back pain: a comprehensive review. Pain Headache Rep. 2019;23(9):1–12.
Oehmi D, Goldschlager T, Rosenfeld J, Ghosh P, Jenken G. The role of stem cell therapies in degenerative lumbar spine disease: a review. Neurosurg Rev. 2015;38(3):429–45.
Feng G, Zhao X, Liu H, Zhang H, Chen X, Shi R, et al. Transplantation of mesenchymal stem cells and nucleus pulposus cells in a degenerative disc model in rabbits: a comparison of 2 cell types as potential candidates for disc regeneration. J Neurosurg Spine. 2011;14(3):322–9.
Henriksson HB, Svanvik T, Jonsson M, Hagman M, Horn M, Lindahl A, et al. Transplantation of human mesenchymal cells into intervertebral discs in a xenogeneic porcine model. Spine (Phila Pa 1976). 2009;34(2):141–8.
Hiyama A, Mochida J, Iwashina T, Omi H, Watanabe T, Serigano K, et al. Transplantation of mesenchymal stem cells in a canine disc degeneration model. J Orthop Res. 2008;26(5):589–600.
Vadala G, Russo F, Musumeci M, D’Este M, Cattani C, Catanzaro G, et al. Clinically relevant hydrogel-based on hyaluronic acid and platelet-rich plasma as a carrier for mesenchymal stem cells: rheological and biological characterization. J Orthop Res. 2017;35(10):2109–16.
Vadala G, Sowa G, Hubert M, Gilbertson L, Denaro V, Kang G. Mesenchymal stem cells injection in degenerated intervertebral disc: cell leakage may induce osteophyte formation. J Tiss Engg Regen Med. 2012;6(5):348–55.
Wangler S, Peroglio M, Menzel U, Benneker L, HaglunD L, Sakai D, Alini M, Grad S. Mesenchymal stem cell homing into intervertebral discs enhances the tie-2 positive progenitor cell population, prevents cell death, and induces a proliferative response. Spine. 2019;44(23):1613–22.
Colombini A, Ceriani C, Banfi G, et al. Fibrin in intervertebral disc tissue engineering. Tissue Eng Part B Rev. 2014;20(6):713–21.
Yin W, Pauza K, Olan W, Doerzbacher J, Thorne K. Intradiscal injection of fibrin sealant for the treatment of symptomatic lumbar internal disc disruption: results of a prospective multicenter pilot study with 24-month follow up. Pain Med. 2014;15(1):16–31.
Zhang C, Berven SH, Fortin M, et al. Adjacent segment degeneration versus disease after lumbar spine fusion for degenerative pathology: a systematic review with meta-analysis of the literature. Clin Spine Surg. 2016;29(1):21–9.
Taylor CA, Braza D, Rice JB, Dillingham T. The incidence of peripheral nerve injury in extremity trauma. Am J Phys Med Rehabil. 2008;87(5):381–5.
Benowitz LI, Popovich PG. Inflammation and axon regeneration. Curr Opin Neurol. 2011;24:577–83.
Stoll G, Jander S, Myers RR. Degeneration and regeneration of the peripheral nervous system: from Augustus Waller’s observations to neuroinflammation. J Peripheral Nerve Syst. 2002;7:13–27.
Deumens R, Bozkurt A, Meek MF, et al. Repairing injured peripheral nerves: bridging the gap. Prog Neurobiol. 2010;92(3):245–76.
Carr MJ, Johnston AP. Schwann cells as drivers of tissue repair and regeneration. Curr Opin Neurobiol. 2017;47:52–7.
Ide C. Peripheral nerve regeneration. Neurosci Res. 1996;25:101–21.
Gaudet AD, Popovich PG, Ramer MS. Wallerian degeneration: gaining perspective on inflammatory events after peripheral nerve injury. J Neuroinflammation. 2011;8:110.
Webber C, Zochodne D. The nerve regenerative microenvironment: early behavior and partnership of axons and Schwann cells. Exp Neurol. 2010;223:51–9.
Fu SY, Gordon T. The cellular and molecular basis of peripheral nerve regeneration. Mol Neurobiol. 1997;14:67–116.
Schneidt P, Friede RL. Myelin phagocytosis in Wallerian degeneration. Properties of millipore diffusion chambers and immunohistochemical identification of cell populations. Acta Neuropathol. 1987;75:77–84.
Chen P, Piao X, Bonaldo P. Role of macrophages in Wallerian degeneration and axonal regeneration after peripheral nerve injury. Acta Neuropathol. 2015;130(5):605–18.
Shin Y, Gu X, Zhang R, Qian T, Li S, Yi S. Biological characteristics of dynamic expression of nerve regeneration related to growth factors in dorsal root ganglia after peripheral nerve injury. Neural Regen Res. 2020;15(8):1502–9.
Seddon HJ. Peripheral nerve injuries. Medical Research Council. Medical Report Series 282. London: Her Majesty’s Stationery Office; 1954.
Sunderland S. Rate of regeneration of I: sensory fibers and II: motor fibers. Arch Neurol Psychiatr. 1947;58:1–14.
Gordon T. Electrical stimulation to enhance axon regeneration after peripheral nerve injuries in the animal models and humans. Neurotherapeutics. 2016;13(2):295–310.
Colloca L, Ludman T, Bouhassira D, Baron R, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;16(3):17002.
Miclescu A, Straamann A, Gkatziani P, Butler S, Karlsten R, Gordh T. Chronic neuropathic pain after traumatic peripheral nerve injuries in the upper extremity: prevalence, demographic and surgical determinants, impact on health and on pain medications. Scand J Pain. 2019;20(1):95–108.
Yu W, Wang J, Yin J. Platelet-rich plasma: a promising product for treatment of peripheral nerve regeneration after nerve injury. Int J Neurosci. 2012;121(4):176–80.
Bastami F, Vares P, Khojasteh A. Healing effects of platelet-rich plasma on peripheral nerve injuries. J Craniofac Surg. 2017;28(1):e49–57.
Afsar SI, Yemisci OU, Cetin N. The role of platelet-rich plasma in peripheral nerve injuries. J Clin Anal Med. 2015;6(suppl 6):905–8.
Lopez JC, Cortes H, Ceballos EG, Pizarro LQ. Platelet-rich plasma in treating peripheral neuropathic pain. Preliminary report. Rev Soc Esp Dolor. 2018;25(5):263–70.
Cass S. Ultrasound-guided nerve hydrodissection: what is it? A review of literature. Curr Sports Med Rep. 2016;15(1):20–2.
Nwawka K, Miller TT. Ultrasound-guided peripheral nerve injection techniques. Am J Roentgen. 2016;207(3):507–16.
Purita J, Lana JFSD, Kolber M, Rodriguez BL, Mosaner T, Santos GS, Caliari-Oliveira C, Huber SC. Bone marrow-derived products: a classification proposal –bone marrow aspirate, bone marrow aspirate concentrate or hybrid? World J Stem Cells. 2020;12(4):1–9.
Acknowledgment
First and foremost, to the Faithful God who allowed me to finish this manuscript during these challenging times of COVID19 pandemic, who kept me busy writing but at the same time keeping us safe from infection.
My family: my wife Kyna de Castro and two kids, Rafael Bennett and Zarah Francine de Castro, for their constant and unwavering support.
To my colleagues who inspired me to move on.
Psalm 84:11 – “For the Lord God is a sun and shield; the Lord bestows favor and honor. No good thing does He withhold from those who walk uprightly.”
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
de Castro, J.C. (2022). Regenerative Medicine Procedures Under Ultrasound Guidance. In: El Miedany, Y. (eds) Musculoskeletal Ultrasound-Guided Regenerative Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-98256-0_14
Download citation
DOI: https://doi.org/10.1007/978-3-030-98256-0_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-98255-3
Online ISBN: 978-3-030-98256-0
eBook Packages: MedicineMedicine (R0)